-

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

The Company to host an earnings conference call via webcast

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day.

The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data accurately reflects the Company's value and complies with all regulatory requirements.

Conference Call and Webcast Details

The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, March 28, 2025, at 10:30AM ET.

The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx.

***Participant Dial-In Details***

Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name.

USA / International Toll +1 (646) 307-1963
USA - Toll-Free (800) 715-9871
Canada - Toll-Free (800) 715-9871

***Webcast Details***

Attendee URL:
https://events.q4inc.com/attendee/849565157

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Contacts

Investor Relations
investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$nvda
$xbi
Hashtags
#AI
#DrugDiscovery
#TechBio
#antibodies
#foundationai
#generativeai
#llm

Contacts

Investor Relations
investors@ipatherapeutics.com

Social Media Profiles
Linkedin
IPA on X
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today unveiled the first public demonstration of ReefIQ™, its biological context layer for AI drug discovery, running on AMD Instinct™ at AMD’s Advancing AI 2026 in San Francisco. MindWalk is featured in the AMD Instinct™ Demo Showcase, appearing in one of four custom demo vignettes, with an accompanying video interview distributed through AMD’s channels. The demonstration is the first...

MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today reported financial results for the fiscal year ended April 30, 2026. All figures are in Canadian dollars unless otherwise noted. Fiscal 2026 was the year MindWalk completed its transition from building its technology to deploying it. Revenue grew 46% year over year, gross margin expanded, the net loss narrowed by more than half, and the Company divested a non-core business to conc...

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: HYFT), a Bio-Native AI company, today announced that it will report financial results for the fourth quarter and full fiscal year 2026 and host a conference call on Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast...
Back to Newsroom